



**VIDANT HEALTH™**

## **Vidant Covid Outpatient Treatment (3/02/22)**

Patients should be within 7 day window for mAb therapy and within 5 day window for oral therapy.

**All individuals should be within 7 days of sx. onset and have mild/mod disease (spO2 > 92%) regardless of other criteria. No patient > 7 days from sx onset should receive therapy. Patients who got Evusheld do NOT qualify for mAb therapy.**

**High risk patients who are within the 7 day window qualify for therapy:**

- Recipients of a solid organ transplant
- Rheumatologic and dermatologic patients on immunosuppressive drugs (DMARDs, biologics, and  $\geq 20$ mg prednisone/day)
- Patients with/undergoing stem cell transplant
- Patients with HIV (especially with CD4 counts  $\leq 200$  or  $< 15\%$  CD4)
- Those with primary immunodeficiency (Common Variable Immunodeficiency, Hypogammaglobulinemia, etc)
- Other patients deemed immunosuppressed by provider who are also found to be non-responders (lab evidence of non-reactive anti-spike protein antibody  $> 14$  days from booster or completed vaccine series)
- Adults who are NOT completely vaccinated - patients are considered vaccinated if they have had the booster, OR completed the Pfizer/Moderna vaccine in the last 5 months OR the J&J within the last 2 months.
- Age  $\geq 55$  OR BMI  $\geq 30$  OR Diabetes OR Chronic lung, heart, liver, or kidney disease
- Neurologic disease including Parkinsons, dementia, MS, spinal cord disease.
- Hematologic diseases such as sickle cell or cytopenias OR any active malignancy (cancer)

**ORAL THERAPIES ONLY AVAILABLE IN SELECT PHARMACIES. In order to prescribe therapy you may:**

- Access the EHR and prescribe mAb or orals using [Covid Outpatient Antiviral Therapy](#) order set. No restrictions.
  - ECU Pharmacy/ Moye Blvd typically has oral meds. Or check <https://covid19.ncdhhs.gov/FindTreatment>
- Consult Covid Virtual Clinic with the EHR using [AMB REFERRAL TO COVID VIRTUAL CLINIC](#) or call 252-830-2021
- Any person (patient or provider) can call the hotline (252 847-6500) M-F 8am-4pm. If needed the hotline can route patients to the Covid Virtual Clinic for oral treatment.

### **-----Treatment Options-----**

**Preferred Option - Paxlovid (nirmatrelvir/ritonavir)** - Only available under EUA. 5 day window from sx onset. Preferred agent with superior efficacy and ease of use. Multiple **SERIOUS** drug interactions. Works by inhibiting viral replication. Adjust dose for CrCl 30-60. Not indicated for CrCl  $< 30$ . Limited supply in certain community pharmacies and ECU Health.

**Option #2 - Sotrovimab or Bebtelovimab** - Only available under EUA in 7 day window. Monoclonal Antibody infusion. If patient unwilling/unable, or antibody not available, consider other options.

**Option #3 - Lagevrio (molnupiravir)** - Only available under EUA. 5 day window from sx onset. 4 capsules twice a day for 5 days. Probably less efficacious. Works by inducing errors in DNA transcription and is therefore mutagenic/teratogenic. **Requires (-) pregnancy test** in women of childbearing age. **Cannot use in patients < age 18**. Few drug interactions. Limited supply in certain community pharmacies and ECU Health.

**Option #4 Luvox (fluvoxamine)** - FDA approved for depression but off label for covid. 100mg po bid x 10 days. Off label use though studies suggest may reduce need for hospitalization. NIH currently states "insufficient evidence to recommend either for or against use"

**For all other patients within the 5 day window with mild/mod disease who, per clinician's judgment, are at high risk for progression to severe COVID-19, provider may consider therapy with Paxlovid, molnupiravir or fluvoxamine.**